Literature DB >> 9039772

MHC class II restricted antigen presentation.

J Pieters1.   

Abstract

Presentation of antigenic peptides by MHC class II molecules to CD4(+) T cells requires many events in both the biosynthetic and endocytic pathways that must all occur in a controlled and coordinated fashion. In recent years the roles of two important chaperones, the invariant chain and the HLA-DM dimer, in promoting the acquisition of peptides by MHC class II molecules have largely been elucidated. The different compartments within the endosomal/lysosomal pathway that are involved in peptide loading are now being characterized. In addition to the specialized MHC class II compartments that exist in antigen-presenting cells, other intracellular compartments may also be involved in peptide loading. The precise mechanisms and intracellular sites of MHC class II peptide loading appear to dictate the nature of the T-cell epitopes presented by the antigen-presenting cell.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9039772     DOI: 10.1016/s0952-7915(97)80164-1

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  23 in total

1.  Two distinct domains within CIITA mediate self-association: involvement of the GTP-binding and leucine-rich repeat domains.

Authors:  M W Linhoff; J A Harton; D E Cressman; B K Martin; J P Ting
Journal:  Mol Cell Biol       Date:  2001-05       Impact factor: 4.272

Review 2.  Class II transactivator: mastering the art of major histocompatibility complex expression.

Authors:  J A Harton; J P Ting
Journal:  Mol Cell Biol       Date:  2000-09       Impact factor: 4.272

3.  Downregulation of CIITA function by protein kinase a (PKA)-mediated phosphorylation: mechanism of prostaglandin E, cyclic AMP, and PKA inhibition of class II major histocompatibility complex expression in monocytic lines.

Authors:  G Li; J A Harton; X Zhu; J P Ting
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 4.  Diversity in MHC class II antigen presentation.

Authors:  John H Robinson; Alexei A Delvig
Journal:  Immunology       Date:  2002-03       Impact factor: 7.397

5.  Intracellular trafficking pathway of newly synthesized CD1b molecules.

Authors:  V Briken; R M Jackman; S Dasgupta; S Hoening; S A Porcelli
Journal:  EMBO J       Date:  2002-02-15       Impact factor: 11.598

Review 6.  Regulation and function of class II major histocompatibility complex, CD40, and B7 expression in macrophages and microglia: Implications in neurological diseases.

Authors:  George M O'Keefe; Vince T Nguyen; Etty N Benveniste
Journal:  J Neurovirol       Date:  2002-12       Impact factor: 2.643

7.  Physical and genetic mapping of the rainbow trout major histocompatibility regions: evidence for duplication of the class I region.

Authors:  Ruth B Phillips; Ana Zimmerman; Marc A Noakes; Yniv Palti; Matt R W Morasch; Lisa Eiben; Sandra S Ristow; Gary H Thorgaard; John D Hansen
Journal:  Immunogenetics       Date:  2003-10-18       Impact factor: 2.846

8.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

Review 9.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

10.  Epstein-Barr virus gp42 is posttranslationally modified to produce soluble gp42 that mediates HLA class II immune evasion.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Sinéad Keating; Raquel Gomez; Kees L M C Franken; Tom H M Ottenhoff; Melanie Spriggs; Ton N Schumacher; Lindsey M Hutt-Fletcher; Martin Rowe; Emmanuel J H J Wiertz
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.